MARTIN JAY SMILKSTEIN, M.D.
Osteopathic Medicine at Us Veterans Hospital Rd, Portland, OR
License number
Oregon 17517
Category
Osteopathic Medicine
Type
Medical Toxicology
Address
Address
3710 SW Us Veterans Hospital Rd, Portland, OR 97239
Phone
(503) 220-8262
(503) 227-1814
(503) 224-3479 (Fax)
(503) 227-1814
(503) 224-3479 (Fax)
Personal information
See more information about MARTIN JAY SMILKSTEIN at radaris.comName
Address
Phone
2536 NW Overton St, Portland, OR 97210
2536 Overton St, Portland, OR 97210
2536 Nwoverton St, Portland, OR 97210
Professional information
See more information about MARTIN JAY SMILKSTEIN at trustoria.com
Inactive Isomer Compositions For Use As Drug-Resistance-Reversal Agents And In Prophylactic Treatment
Inactive Isomer Compositions For Use As Drug-Resistance-Reversal Agents And In Prophylactic Treatment
US Patent:
2008019, Aug 14, 2008
Filed:
Apr 16, 2008
Appl. No.:
12/104267
Inventors:
Martin J. Smilkstein - Portland OR, US
International Classification:
A61K 31/4402, A61P 37/08
US Classification:
514357
Abstract:
A method of using inactive isomer compositions as drug-resistance-reversal agents and in prophylactic treatment includes the steps of selecting an antihistaminically-inactive isomer of a preselected antihistamine, and making stereoselective use of the antihistaminically-inactive isomer for a clinical purposes. The making step includes choosing one of the following clinical purposes for which to make stereoselective use of the antihistaminically-inactive isomer: treatment of malaria, prophylaxis of malaria; and treatment of drug-resistant malignancies. The step of selecting an antihistaminically-inactive isomer involves preselecting an antihistamine from the group consisting of chlorpheniramine (−), brompheniramine (−), fluorpheniramine (−), pheniramine (−), bromodiphenhydramine, doxylamine, prophenpyridamine, chlorcyclizine, dimethindene (+), carbinoxamine (+), chlorphenoxamine, clemastine, orphenadrine, hydroxyzine, meclizine, and buclizine. Various inactive isomer compositions are disclosed for the above-described clinical purposes.
Inactive Isomer Compositions For Use As Drug-Resistance-Reversal Agents And In Prophylactic Treatment
Inactive Isomer Compositions For Use As Drug-Resistance-Reversal Agents And In Prophylactic Treatment
US Patent:
2005027, Dec 8, 2005
Filed:
Jun 2, 2005
Appl. No.:
11/145467
Inventors:
Martin Smilkstein - Portland OR, US
International Classification:
A61K031/495, A61K031/4172, A61K031/137
US Classification:
514255040, 514400000, 514649000
Abstract:
A method of using inactive isomer compositions as drug-resistance-reversal agents and in prophylactic treatment includes the steps of selecting an antihistaminically-inactive isomer of a preselected antihistamine, and making stereoselective use of the antihistaminically-inactive isomer for a clinical purposes. The making step includes choosing one of the following clinical purposes for which to make stereoselective use of the antihistaminically-inactive isomer: treatment of malaria, prophylaxis of malaria; and treatment of drug-resistant malignancies. The step of selecting an antihistaminically-inactive isomer involves preselecting an antihistamine from the group consisting of chlorpheniramine (−), btompheniramine (−), fluorpheniramine (−), pheniramine (−), bromodiphenhydramine, doxylamine, prophenpyridamine, chlorcyclizine, dimethindene (+), carbinoxamine (+), chlorphenoxamine, clemastine, orphenadrine, hydroxyzine, meclizine, and buclizine. Various inactive isomer compositions are disclosed for the above-described clinical purposes.
Drug Composition And Method For Treating Malaria And Malignancy
Drug Composition And Method For Treating Malaria And Malignancy
US Patent:
2008010, May 8, 2008
Filed:
Feb 10, 2006
Appl. No.:
11/352388
Inventors:
Martin J. Smilkstein - Portland OR, US
International Classification:
A61K 31/135, A61K 31/47, A61P 33/06, A61P 35/00
US Classification:
514313, 514648
Abstract:
A method of treating a malarial infection includes using orphenadrine as part of treating the infection. The method may use orphenadrine alone or in combination with another antimalarial drug, such as chloroquine, or with plural antimalarial drugs. Use of orphenadrine in this way may also be used in a method of providing prophylaxis against a malarial infection, and as part of a method of treating a malignancy.
Dr. Martin J Smilkstein, Portland OR - MD (Doctor of Medicine)
Dr. Martin J Smilkstein, Portland OR - MD (Doctor of Medicine)
Specialties:
Medical Toxicology
Address:
3710 SW Us Veterans Hospital Rd, Portland 97239
(503) 220-8262 (Phone)
(503) 220-8262 (Phone)
Certifications:
Emergency Medicine, 2005, Medical Toxicology, 2000
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Univ Of Ca Davis Sch Of Med
Graduated: 1979
Univ Of Ca Davis Sch Of Med
Graduated: 1979
Compounds Having Antiparasitic Or Anti-Infectious Activity
Compounds Having Antiparasitic Or Anti-Infectious Activity
US Patent:
2014004, Feb 13, 2014
Filed:
Oct 16, 2013
Appl. No.:
14/055757
Inventors:
- Geneva, CH
Martin J. Smilkstein - Portland OR, US
Aaron Nilsen - Portland OR, US
Jeremy Burrows - Eysins, CH
Dennis Kyle - Lithia FL, US
Roman Manetsch - Tampa FL, US
Richard M. Cross - Brandon FL, US
Andrii Monastyrskyi - Tampa FL, US
David L. Flanigan - Riverview FL, US
Martin J. Smilkstein - Portland OR, US
Aaron Nilsen - Portland OR, US
Jeremy Burrows - Eysins, CH
Dennis Kyle - Lithia FL, US
Roman Manetsch - Tampa FL, US
Richard M. Cross - Brandon FL, US
Andrii Monastyrskyi - Tampa FL, US
David L. Flanigan - Riverview FL, US
Assignee:
Oregon Health & Science University - Portland OR
Medicines for Malaria Venture - Geneva 15
University of South Florida - Tampa FL
The Government of the United States of America dba The Department of Veterans Affairs - Washington DC
Medicines for Malaria Venture - Geneva 15
University of South Florida - Tampa FL
The Government of the United States of America dba The Department of Veterans Affairs - Washington DC
International Classification:
C07D 215/233
US Classification:
514312
Abstract:
Compounds of formula I:or formula II:
Compounds Having Antiparasitic Or Anti-Infectious Activity
Compounds Having Antiparasitic Or Anti-Infectious Activity
US Patent:
2012001, Jan 12, 2012
Filed:
Jun 3, 2011
Appl. No.:
13/153347
Inventors:
Michael K. Riscoe - Tualatin OR, US
Jane X. Kelly - Lake Oswego OR, US
Rolf W. Winter - Portland OR, US
David J. Hinrichs - Sherwood OR, US
Martin J. Smilkstein - Portland OR, US
Aaron Nilsen - Portland OR, US
Jane X. Kelly - Lake Oswego OR, US
Rolf W. Winter - Portland OR, US
David J. Hinrichs - Sherwood OR, US
Martin J. Smilkstein - Portland OR, US
Aaron Nilsen - Portland OR, US
International Classification:
A61K 31/47, A61P 33/00
US Classification:
514312
Abstract:
A method for inhibiting a parasitic or infectious disease in a subject, wherein the parasitic or infectious disease is selected from one caused by sp., sp., sp. or , the method comprising administering to the subject a therapeutically effective amount of a compound of formula I:
Aromatic Ketones And Uses Thereof
Aromatic Ketones And Uses Thereof
US Patent:
7829578, Nov 9, 2010
Filed:
Dec 5, 2006
Appl. No.:
11/633509
Inventors:
Michael K. Riscoe - Tualatin OR, US
Rolf W. Winter - Portland OR, US
Jane X. Kelly - Lake Oswego OR, US
Martin J. Smilkstein - Portland OR, US
David J. Hinrichs - Lake Oswego OR, US
Rolf W. Winter - Portland OR, US
Jane X. Kelly - Lake Oswego OR, US
Martin J. Smilkstein - Portland OR, US
David J. Hinrichs - Lake Oswego OR, US
Assignee:
Oregon Health & Science University - Portland OR
U.S. Department of Veterans Affairs - Washington DC
U.S. Department of Veterans Affairs - Washington DC
International Classification:
C07D 215/38, A61K 31/04
US Classification:
514312, 546153, 546159
Abstract:
Aromatic ketones having an extended fluoro-alkyl or fluoro-alkoxy moiety are disclosed. In particular aspects, the compounds comprise substituted 9-acridone, 9-xanthone, 4(1H)-quinolone, 4(1H) pyridone, 1,4-naphthoquinone, 9,10-anthraquinone derivatives. These preparations possess potent pharmacological activity for inhibiting malaria and mosquito-borne () diseases. The haloalkyl/alkoxy aromatic compounds possess significant pharmacological activity, with ICvalues in the nanomolar and sub-nanomolar range, and reduced toxicity against host derived cells and tissues. Methods of using the fluoro-alkyl/alkoxy aromatic compounds in the treatment of malaria and other human and animal diseases are also disclosed. Agricultural uses of the fluoro-alkyl/alkoxy aromatic compounds, such as in control of fungal diseases and in the production of important commercial crops (apples, etc. ), are also presented.
Compounds Having Antiparasitic Or Anti-Infectious Activity
Compounds Having Antiparasitic Or Anti-Infectious Activity
US Patent:
8598354, Dec 3, 2013
Filed:
Jun 3, 2011
Appl. No.:
13/153350
Inventors:
Michael K. Riscoe - Tualatin OR, US
Jane X. Kelly - Lake Oswego OR, US
Rolf W. Winter - Portland OR, US
David J. Hinrichs - Lake Oswego OR, US
Martin J. Smilkstein - Portland OR, US
Aaron Nilsen - Portland OR, US
Jeremy Burrows - Eysins, CH
Dennis Kyle - Lithia FL, US
Roman Manetsch - Tampa FL, US
Richard M. Cross - Brandon FL, US
Andrii Monastyrskyi - Tampa FL, US
David L. Flanigan - Riverview FL, US
Jane X. Kelly - Lake Oswego OR, US
Rolf W. Winter - Portland OR, US
David J. Hinrichs - Lake Oswego OR, US
Martin J. Smilkstein - Portland OR, US
Aaron Nilsen - Portland OR, US
Jeremy Burrows - Eysins, CH
Dennis Kyle - Lithia FL, US
Roman Manetsch - Tampa FL, US
Richard M. Cross - Brandon FL, US
Andrii Monastyrskyi - Tampa FL, US
David L. Flanigan - Riverview FL, US
Assignee:
University of South Florida - Tampa FL
Medicines for Malaria Venture - Geneva
Medicines for Malaria Venture - Geneva
International Classification:
C07D 215/233, A61K 31/47, A61P 31/00, A61P 33/00, A61P 33/02, A61P 33/06
US Classification:
546153, 514312
Abstract:
Compounds of formula I:.
Acridone Compounds
Acridone Compounds
US Patent:
8592447, Nov 26, 2013
Filed:
Nov 13, 2007
Appl. No.:
12/312503
Inventors:
Michael K. Riscoe - Tualatin OR, US
Rolf Winter - Portland OR, US
Jane X. Kelly - Lake Oswego OR, US
David J. Hinrichs - Lake Oswego OR, US
Martin J. Smilkstein - Portland OR, US
Rolf Winter - Portland OR, US
Jane X. Kelly - Lake Oswego OR, US
David J. Hinrichs - Lake Oswego OR, US
Martin J. Smilkstein - Portland OR, US
Assignee:
Oregon Health & Science University - Portland OR
The United States of America, as represented by the Department of Veterans Affairs - Washington DC
The United States of America, as represented by the Department of Veterans Affairs - Washington DC
International Classification:
A61K 31/44, C07D 219/04
US Classification:
514297, 546103
Abstract:
A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.